{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:59:36Z","timestamp":1781305176761,"version":"3.54.1"},"reference-count":62,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec id=\"j_cclm-2016-0638_s_999\">\n<jats:title id=\"d557296e26280\">Background:<\/jats:title>\n<jats:p>Anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies have begun to be considered potentional biomarkers for antiphospholipid syndrome (APS). This cohort study investigate the role of aPS\/PT antibodies as a risk factor for severe APS by evaluating the association between those antibodies and clinical\/laboratory profiles of APS.<\/jats:p><\/jats:sec>\n<jats:sec id=\"j_cclm-2016-0638_s_998\">\n<jats:title id=\"d557296e26288\">Methods:<\/jats:title>\n<jats:p>Plasma\/serum samples from 197 APS patients, 100 healthy subjects and 106 patients with autoimmune diseases were collected. IgG\/IgM aPS\/PT antibodies were assayed using commercial ELISA kit.<\/jats:p><\/jats:sec>\n<jats:sec id=\"j_cclm-2016-0638_s_997\">\n<jats:title id=\"d557296e26296\">Results:<\/jats:title>\n<jats:p>Prevalences of IgG and IgM aPS\/PT (p&lt;0.0001 and p=0.0009, respectively) and their titres (p&lt;0.0001 and p=0.0002, respectively) were significantly higher in thrombosis\/pregnancy group with respect to pregnancy morbidity alone. Prevalences of IgG and IgM aPS\/PT (p&lt;0.0001 and p=0.0004, respectively) and their mean levels (p=0.0001 for both) were significantly higher in the prematurity linked to life-threatening obstetric complications group with respect to miscarriage group. There was a significant relationship between IgG and IgM aPS\/PT (p=0.001 and p=0.0002) and their mean levels were higher (p=0.0004 and p=0.0002, respectively) in the thrombotic microangiopathy group, considered a milestone manifestation of catastrophic APS. The relationship between IgG and IgM aPS\/PT was significant and mean levels were higher in triple positive antiphospholipid antibody patients than in double and single positivity ones (p&lt;0.0001 for all).<\/jats:p><\/jats:sec>\n<jats:sec id=\"j_cclm-2016-0638_s_996\">\n<jats:title id=\"d557296e26304\">Conclusions:<\/jats:title>\n<jats:p>APS\/PT antibodies were associated to severe thrombosis, severe pregnancy complications inducing prematurity, and vascular microangiopathy, all generally associated to high risk APS forms requiring strong therapy.<\/jats:p><\/jats:sec>","DOI":"10.1515\/cclm-2016-0638","type":"journal-article","created":{"date-parts":[[2016,11,6]],"date-time":"2016-11-06T10:01:26Z","timestamp":1478426486000},"page":"890-898","source":"Crossref","is-referenced-by-count":52,"title":["Antiphosphatidylserine\/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome"],"prefix":"10.1515","volume":"55","author":[{"given":"Ariela","family":"Hoxha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mattia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Grava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Ruffatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref471","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1538-7836.2008.03121.x","article-title":"Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification","volume":"6","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2013.11.009","article-title":"Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th international congress on antiphospholipid antibodies","volume":"428","year":"2014","journal-title":"Clin Chim Acta"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/0961203310397082","volume":"20","year":"2011","journal-title":"Lupus"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.thromres.2004.06.035","article-title":"Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies","volume":"114","year":"2004","journal-title":"Thromb Res"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre,case-control study","volume":"50","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","year":"2013","journal-title":"Arthritis Care Res"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"e000131","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","year":"2016","journal-title":"Lupus Sci Med"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/j.1538-7836.2004.00910.x","article-title":"Proposals for the measurement of anti-b2-glycoprotein I antibodies. Standardization group of the European forum on antiphospholipid antibodies","volume":"2","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","year":"2010","journal-title":"J Thromb Haemost"},{"key":"ref211","first-page":"699","article-title":"The presence of anti-phosphatidylserine\/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus","volume":"91","year":"2006","journal-title":"Haematologica"},{"key":"ref561","first-page":"1793","article-title":"Microangiopathic antiphospholipid syndromes (MAPS) revisited\u2014new concepts relating to antiphospholipid antibodies and syndromes","volume":"34","year":"2007","journal-title":"J Rheumatol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acr.20098","article-title":"Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome","volume":"62","year":"2010","journal-title":"Arthritis Care Res"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1160\/TH04-06-0382","article-title":"Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus","volume":"93","year":"2005","journal-title":"Thromb Haemost"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1160\/TH06-05-0287","article-title":"Antibody profile and clinical course in primary antiphospholipid syndrome and pregnancy morbidity","volume":"96","year":"2006","journal-title":"Thromb Haemost"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1160\/TH12-07-0527","article-title":"Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS\/PT) in patients with and without lupus anticoagulant","volume":"109","year":"2013","journal-title":"Thromb Haemost"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1160\/TH13-06-0509","article-title":"Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review","volume":"111","year":"2014","journal-title":"Thromb Haemost"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/j.1538-7836.2004.00910.x","article-title":"Proposals for the measurement of anti-b2-glycoprotein I antibodies. Standardization group of the European forum on antiphospholipid antibodies","volume":"2","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/0961203312441983","article-title":"Antiphosphatidylserine\/prothrombin antibodies in primary antiphospholipid syndrome","volume":"21","year":"2012","journal-title":"Lupus"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1076029612437578","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) as potential markers of antiphospholipid syndrome","volume":"19","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","year":"2010","journal-title":"J Thromb Haemost"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1160\/TH13-06-0509","article-title":"Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review","volume":"111","year":"2014","journal-title":"Thromb Haemost"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1191\/0961203302lu202cr","article-title":"Revisiting the anticardiolipin test and its standardization","volume":"11","year":"2002","journal-title":"Lupus"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/0961203310397082","volume":"20","year":"2011","journal-title":"Lupus"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2","article-title":"Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant","volume":"43","year":"2000","journal-title":"Arthritis Rheum"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12026-013-8421-z","article-title":"Anti-phosphatidylserine\/prothrombin antibodies: an additional diagnostic marker for APS?","volume":"56","year":"2013","journal-title":"Immunol Res"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","year":"2003","journal-title":"Blood"},{"key":"ref231","first-page":"1793","article-title":"Microangiopathic antiphospholipid syndromes (MAPS) revisited\u2014new concepts relating to antiphospholipid antibodies and syndromes","volume":"34","year":"2007","journal-title":"J Rheumatol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12026-013-8421-z","article-title":"Anti-phosphatidylserine\/prothrombin antibodies: an additional diagnostic marker for APS?","volume":"56","year":"2013","journal-title":"Immunol Res"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acr.20098","article-title":"Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome","volume":"62","year":"2010","journal-title":"Arthritis Care Res"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the global anti-phospholipid syndrome score","volume":"52","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1191\/0961203302lu202cr","article-title":"Revisiting the anticardiolipin test and its standardization","volume":"11","year":"2002","journal-title":"Lupus"},{"key":"ref251","first-page":"147","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","year":"2005","journal-title":"Thromb Haemost"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","year":"2003","journal-title":"Blood"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1160\/TH04-06-0382","article-title":"Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus","volume":"93","year":"2005","journal-title":"Thromb Haemost"},{"key":"ref581","first-page":"147","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","year":"2005","journal-title":"Thromb Haemost"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"e000131","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","year":"2016","journal-title":"Lupus Sci Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1160\/TH12-07-0527","article-title":"Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS\/PT) in patients with and without lupus anticoagulant","volume":"109","year":"2013","journal-title":"Thromb Haemost"},{"key":"ref541","first-page":"699","article-title":"The presence of anti-phosphatidylserine\/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus","volume":"91","year":"2006","journal-title":"Haematologica"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the global anti-phospholipid syndrome score","volume":"52","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1160\/TH06-05-0287","article-title":"Antibody profile and clinical course in primary antiphospholipid syndrome and pregnancy morbidity","volume":"96","year":"2006","journal-title":"Thromb Haemost"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1538-7836.2008.03121.x","article-title":"Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification","volume":"6","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref241","first-page":"631","article-title":"Preeclampsia","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2","article-title":"Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant","volume":"43","year":"2000","journal-title":"Arthritis Rheum"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/rheumatology\/35.6.589","article-title":"Phosphatidylserine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant","volume":"35","year":"1996","journal-title":"Br J Rheumatol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.thromres.2013.12.001","article-title":"Validation of a commercially available kit to detect anti-phosphatidylserine\/prothrombin antibodies in a cohort of systemic lupus erythematosus patients","volume":"133","year":"2014","journal-title":"Thromb Res"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1076029612437578","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) as potential markers of antiphospholipid syndrome","volume":"19","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/0961203312441983","article-title":"Antiphosphatidylserine\/prothrombin antibodies in primary antiphospholipid syndrome","volume":"21","year":"2012","journal-title":"Lupus"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2015.10.003","article-title":"Antibodies to phosphatidylserine\/prothrombin complex in antiphospholipid syndrome: analytical and clinical perspectives","volume":"73","year":"2016","journal-title":"Adv Clin Chem"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2015.10.003","article-title":"Antibodies to phosphatidylserine\/prothrombin complex in antiphospholipid syndrome: analytical and clinical perspectives","volume":"73","year":"2016","journal-title":"Adv Clin Chem"},{"key":"ref421","first-page":"1265","article-title":"Relationship between antiphosphatidylserine\/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome","volume":"53","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"ref91","first-page":"1265","article-title":"Relationship between antiphosphatidylserine\/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome","volume":"53","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.thromres.2013.12.001","article-title":"Validation of a commercially available kit to detect anti-phosphatidylserine\/prothrombin antibodies in a cohort of systemic lupus erythematosus patients","volume":"133","year":"2014","journal-title":"Thromb Res"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","year":"2013","journal-title":"Arthritis Care Res"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre,case-control study","volume":"50","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2013.11.009","article-title":"Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th international congress on antiphospholipid antibodies","volume":"428","year":"2014","journal-title":"Clin Chim Acta"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/rheumatology\/35.6.589","article-title":"Phosphatidylserine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant","volume":"35","year":"1996","journal-title":"Br J Rheumatol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Antiphospholipid syndrome study group of Italian society of rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref571","first-page":"631","article-title":"Preeclampsia","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.thromres.2004.06.035","article-title":"Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies","volume":"114","year":"2004","journal-title":"Thromb Res"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Antiphospholipid syndrome study group of Italian society of rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2017.55.issue-6\/cclm-2016-0638\/cclm-2016-0638.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2016-0638\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:55:19Z","timestamp":1619049319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2016-0638\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":62,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1515\/cclm-2016-0638","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}